CBX3/heterochromatin protein 1 gamma is significantly upregulated in patients with non–small cell lung cancer

Chang, Shih Chieh; Lai, Yi Chun; Chen, Yen‐Chung; Wang, Nai Kuan; Wang, Wei Shu; Lai, Jiun-I

doi:10.1111/ajco.12820

Cited by 43 publications

(41 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Elevated expression of CBX3 was found in prostate cancer [14] , breast cancer [15] , lung cancer and colorectal cancer [16] . Overexpression of CBX3 was correlated with poor prognosis in tongue squamous cell carcinoma [17] , non-small cell lung cancer [18] and prostate cancer [14] . Increased CBX5 expression was reported in prostate cancer [19] , [20] and breast cancer [15] .…”

Section: Discussionmentioning

confidence: 98%

CBX1 Indicates Poor Outcomes and Exerts Oncogenic Activity in Hepatocellular Carcinoma

Yang

Pan

Qing

et al. 2018

Translational Oncology

View full text Add to dashboard Cite

Dysregulation of chromobox proteins contributes to the progression of human diseases. CBX1 has been implicated in epigenetic control of chromatin structure and gene expression, but its role in human cancers remains largely unknown. Here we show that CBX1 exhibits oncogenic activities in hepatocellular carcinoma (HCC) and indicates poor outcomes. The expression of CBX1 was noticeably increased, at both mRNA and protein levels, in HCC tissues and cell lines, compared with the nontumorous ones. High CBX1 expression was significantly associated with larger tumor size, poor tumor differentiation and tumor vascular invasion. Patients with elevated expression of CBX1 were frequently accompanied with unfavorable overall and disease-free survivals in two independent cohorts consisting of 648 HCC cases. The prognostic value of CBX1 was further confirmed by stratified survival analyses. Multivariate cox regression model suggested CBX1 as an independent factor for overall survival (hazard ratio = 1.735, 95% confident interval: 1.342–2.244, P < .001). In vitro data demonstrated that CBX1 overexpression promoted cell proliferation and migration, whereas the knockdown of CBX1 resulted in the opposite phenotypes. Mechanistically, CBX1 interacted with transcription factor HMGA2 to activate the Wnt/β-Catenin signaling pathway. Suppression of β-Catenin by siRNA or specific inhibitor XAV-939 markedly attenuated CBX1-mediated cell growth. Collectively, our findings indicate that CBX1 functions as an oncogene and may serve as a potential prognostic biomarker in HCC.

show abstract

Section: Discussionmentioning

confidence: 98%

CBX1 Indicates Poor Outcomes and Exerts Oncogenic Activity in Hepatocellular Carcinoma

Yang

Pan

Qing

et al. 2018

Translational Oncology

View full text Add to dashboard Cite

show abstract

“…Some studies have indicated that CBX3 expression is upregulated in many human cancers, such as cervical cancer, breast cancer and lung cancer 27 , 32 - 34 . Suppression of CBX3 expression had an inhibitory effect on cervical cancer cell growth, demonstrating that CBX3 might be an effective therapeutic target for cervical cancer 33 .…”

Section: Discussionmentioning

confidence: 99%

The Prognostic Value of the Chromobox Family in Human Ovarian Cancer

Pan

Song

et al. 2020

J. Cancer

View full text Add to dashboard Cite

Ovarian cancer is one of the most lethal gynecologic tumors in women and has a poor prognosis. The purpose of our study was to identify new prognostic markers in ovarian cancer. We examined the prognostic roles of mRNA expression of the chromobox (CBX) family in patients with ovarian cancer utilizing the Kaplan-Meier plotter database. The prognostic values and expression levels of CBX members associated with prognosis were further evaluated using KM plotter in diverse subgroups and immunohistochemistry (IHC) analysis in ovarian carcinoma. The results revealed that elevated CBX1-3 mRNA expression may predict poor overall survival (OS) and progression-free survival (PFS) outcomes in patients with ovarian cancer. Notably, in women with ovarian cancer, increased CBX1 mRNA expression was linked to a short OS in all stages and in the grade II and grade III subgroups. Additionally, CBX2 and CBX3 were strongly related to short OS in stage III+IV patients, and a link between high CBX3 mRNA expression and unfavorable OS in grade II patients was observed. High expression levels of CBX1 and CBX3 were significantly associated with chemotherapy resistance in ovarian cancer patients. IHC staining showed that the CBX1-3 proteins were upregulated in serous ovarian carcinoma tissues compared with normal ovarian tissues. Therefore, our results indicated that CBX1-3 could be attractive biomarkers for predicting poor prognosis of ovarian cancer.

show abstract

“…Similar observation was obtained in tongue squamous cell carcinoma, in which overexpression of CBX3 inhibited p21 and promoted G1/S cell cycle transition [ 14 ]. In addition, CBX3 was found overexpressed in breast cancer and non-small cell lung cancer tissues, and its expression may predict the poor prognosis of patients with these cancers [ 15 , 16 ]. A recent study showed that CBX3 deficiency may mitigate the tumor burden in mice with treatment of tumor-killing CD8+ cells, further suggesting its rational role as a therapeutic target in solid tumor treatment [ 17 ].…”

Section: Introductionmentioning

confidence: 99%

Overexpression of CBX3 in Pancreatic Adenocarcinoma Promotes Cell Cycle Transition-Associated Tumor Progression

Chen

Cheng

et al. 2018

IJMS

View full text Add to dashboard Cite

Background: Previous studies showed that Chromobox protein homolog 3 (CBX3) was overexpressed in several types of human cancers, however its pattern and role in pancreatic adenocarcinoma (PAAD) has not yet been understood. The aim of this study was to identify the expression and function of CBX3 in PAAD. Methods: Data of transcriptomic and protein expression of CBX3 in PAAD were collected from different databases and analyzed. The in vitro and in vivo role of CBX3 in PAAD was examined. Results: CBX3 was overexpressed in human PAAD tissues, which was associated with poor prognosis of overall and disease-free survival of the patients. Overexpression of CBX3 induced the in vitro proliferation, anchorage-free growth, migration and invasion of the PAAD cells, and led to in vivo growth of orthotoptic PAAD tumors in mice. GO and KEGG pathway analysis, as well as experimental observation showed that CBX3 may be associated with cell cycle transition of PAAD cells, and cyclin-dependent kinase 1 (CDK1) and proliferating cell nuclear antigen (PCNA) may mediate the tumor-promoting action of CBX3. CDK1 knockdown attenuated the cell cycle transition, proliferation and invasion of CBX3-overexpressing PAAD cells. Conclusion: Our findings suggest the tumor-promoting role of CBX3 in PAAD to be targeted by novel therapeutic strategies.

show abstract

CBX3/heterochromatin protein 1 gamma is significantly upregulated in patients with non–small cell lung cancer

Abstract: We report a significant upregulation of CBX3/HP1-gamma in NSCLC patients, and also a possible relationship between CBX3/HP1-gamma expression and EGFR mutation.

Cited by 43 publications

References 30 publications

CBX1 Indicates Poor Outcomes and Exerts Oncogenic Activity in Hepatocellular Carcinoma

CBX1 Indicates Poor Outcomes and Exerts Oncogenic Activity in Hepatocellular Carcinoma

The Prognostic Value of the Chromobox Family in Human Ovarian Cancer

Overexpression of CBX3 in Pancreatic Adenocarcinoma Promotes Cell Cycle Transition-Associated Tumor Progression

Contact Info

Product

Resources

About